Improving Lives Through Imaging & Targeted Therapy

Learn More
What do we do?

Theranostics

Imaging / Therapy

Cell>Point

Cell>Point is a late stage Phase 3 biotech company specializing in the field of theranostic nuclear medicine through chelation technologies focused in cancer, cardiovascular, neuroendocrine, diabetes and ischemia-based diseases.

The company was established in 2001 to develop and commercialize molecular imaging and targeted therapeutics based on 5 platform technologies licensed from The University of Texas MD Cancer Center.

Our Lead Product – Oncardia

Cell>Point’s lead product in clinical development is ethylenedicysteine-glucosamine which the company registered under the trademark “Oncardia”. With applications in cancer and cardiovascular disease, Oncardia can be radiolabeled or complexed with cold metals to create a range of nuclear imaging and therapeutic products.  Oncardia’s mechanism of action allows it to target the diseased cell and then deliver its radionuclide or cold metal into the cell nucleus.  Cell>Point refers to this as intra-nuclear therapy. Oncardia can be conveniently labeled with technetium-99m (99mTc) for imaging with SPECT and SPECT/CT camera systems or gallium-68 (68Ga) for imaging with PET and PET/CT camera systems. For therapy, there are two choices. Oncardia can be complexed with a cold metal for intra-nuclear metallic therapy such as platinum or rhenium-187 (187Re), or it can be labeled with radionuclides like lutetium-177 or rhenium-188 for intra-nuclear radiotherapy.

Read More
5

Platform Technologies Acquired from the University of Texas M.D. Anderson Cancer Center

4

Platform Technologies Are Based on Chelation Chemistry

14

Molecular Imaging Agents

4

Targeted Intra-Nuclear Therapeutics

140

Patents Granted Worldwide

12

Patents Pending

Have questions?

Frequently Asked

Read All FAQs

Products & Technology

Theranostics

Theranostic medicine is a major step forward in making personalized medicine a reality. At Cell>Point, theranostics is the combination of target specific diagnostic imaging and compatible target specific therapy at the molecular level.

Explore

Cancer Imaging

Until Oncardia, the only way to image cancer is with expensive PET cameras. This is about to change.

Explore

Cardiac Imaging

Nuclear cardiology imaging needs an agent that eliminates the stress test. At Cell>Point we are making that a reality.

Explore

News & Publications

MedAxiom Announces Industry Partnership With Cell>Point

MedAxiom Announces Industry Partnership With Cell>Point with Video Cell>Point, improving lives through imaging and targeted therapy. Partner News…

Read

Cell>Point plans to expedite research program on 99mTc-EC-Amifostine and 177Lu-EC- Amifostine as a potentially effective theranostic technology for COVID-19

CENTENNIAL, Colorado, March 24, 2020 – Cell>Point announced today its plans to move forward with its research program…

Read

Cell>Point Expanding Theranostic Clinical Research to Include Platinum and 177Lu Targeted Therapy to Compliment Oncardia Imaging Platform

CENTENNIAL, Colorado, January 21, 2020 – Cell>Point announced today, based on its sponsored chelator and therapeutic research conducted…

Read

Cell>Point announced today that it plans to begin patient recruitment for its Phase 2b cardiovascular imaging study in patients suffering from coronary artery disease using the new one-vial Oncardia

CENTENNIAL, Colorado, May 17, 2019 – Cell>Point announced today that it plans to begin patient recruitment for its…

Read

Latest Findings

On Research

Learn More